Related Experiment Video
Updated: Aug 12, 2026

A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
Published on: July 14, 2023
The current status of gene therapy
1Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
Locoregionally recurrent head and neck squamous cell carcinoma is a logical target for direct delivery of gene therapy approaches. Because the protein p53 plays a role in cell cycle regulation and in apoptosis, p53 gene transfer was initially tested in head and neck cancer patients by injecting the primary or regional tumor with an adenoviral vector possessing wild-type p53. Adenoviral p53 was demonstrated to be safe and well tolerated; furthermore, activity was observed. Several randomized studies of adenoviral p53 are now under way in patients with head and neck squamous cell carcinoma to determine its role as a surgical adjuvant in untreated disease and in combination with DNA-damaging agents.
Insights
Gene therapy using adenoviral p53 shows safety and activity in recurrent head and neck squamous cell carcinoma. Further studies are evaluating its role alongside surgery and DNA-damaging agents.
Area of Science:
- Oncology
- Gene Therapy
- Head and Neck Cancer Research
Background:
- Locoregionally recurrent head and neck squamous cell carcinoma presents a challenge for treatment.
- The p53 protein is crucial for cell cycle regulation and apoptosis, making it a target for cancer therapy.
Purpose of the Study:
- To evaluate the safety and efficacy of direct gene transfer of wild-type p53 into head and neck tumors.
- To explore the potential of adenoviral p53 as a therapeutic agent for recurrent head and neck squamous cell carcinoma.
Main Methods:
- Direct intratumoral injection of an adenoviral vector carrying wild-type p53 into primary or regional tumors.
- Observation of safety, tolerability, and anti-cancer activity.
Main Results:
- Adenoviral p53 gene transfer was found to be safe and well-tolerated in patients.
- Demonstrated observable anti-cancer activity in treated patients.
Conclusions:
- Adenoviral p53 is a safe and potentially active therapeutic strategy for head and neck squamous cell carcinoma.
- Ongoing randomized trials are investigating adenoviral p53 as an adjuvant to surgery and in combination with chemotherapy.
More Related Videos
03:52Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications
Published on: February 9, 2024
10:00Development of Mesenchymal Stem Cell Membrane-Enveloped Nanovesicles for Enhanced Gene Delivery
Published on: February 17, 2026
Related Concept Videos
What is Genetic Engineering?
In-vitro Mutagenesis
Gene Therapy
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Microorganisms in Medicine and Therapeutics